Document is current

Article History

Received: 23 March 2023

Accepted: 9 August 2023

First Online: 15 September 2023

Declarations

:

: VOYAGE 2 was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. The study protocol was approved by ethics committees at each site. All participants provided written informed consent.

: Not applicable.

: WT has received research grants, consulting or speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Merck Sharp & Dohme, Novartis, Ono-Pharma, Pfizer, and UCB. AE has received research funding from AbbVie, Bristol Myers Squibb, the Danish National Psoriasis Foundation, Eli Lilly, Janssen Pharmaceuticals, the Kongelig Hofbuntmager Aage Bang Foundation, Novartis, Pfizer, and the Simon Spies Foundation, and honoraria as a consultant and/or speaker from AbbVie, Almirall, Bristol Myers Squibb, Dermavant, Eli Lilly, Galapagos NV, Galderma, Janssen Pharmaceuticals, LEO Pharma, Mylan, Novartis, Pfizer, Samsung Bioepis, Sun Pharmaceuticals, UCB, UNION Therapeutics, and Zuellig Pharma. ES has received honoraria/speaker fees from AbbVie, Eli Lilly, Janssen Pharmaceuticals, LEO Pharma, Novartis, MSD, Sanofi and UCB, and an independent research grant from Pfizer. PG is an employee of Janssen-Cilag Ltd, High Wycombe, UK. AT is an employee of Janssen-Cilag AB, Solna, Sweden. JB is an employee of Janssen Pharmaceutica NV, Beerse, Belgium. SW is an employee of Janssen-Cilag GmbH, Neuss, Germany. DM has received research grants and speaker fees from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, and UCB.